Kidney Cancer

P=N/A, N=90, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting

In addition, we discovered the relationship between genetic mutations and immune checkpoints. This work highlights the single-cell transcriptome and DNA-level information of this rare ccRCC and will provide more genetic insights and references into this rare disease.

Finally, tumouroids were subjected to treatment with Pazopanib (Votrient™), a tyrosine kinase inhibitor (TKI) used in the treatment of advanced RCC...Tumouroids mimic the original tumour and its microenvironment and elicit response to drugs that target both the tumour cells and the tumour microenvironment. This is a patient-specific in vitro tool that addresses the unmet clinical need for predicting an individual's response to therapy.

P2, N=45, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Nov 2025 --> Jul 2025

P=N/A, N=248, Active, not recruiting, Regina Elena Cancer Institute | Trial primary completion date: Jul 2025 --> Jul 2028 | Recruiting --> Active, not recruiting

P2, N=62, Active, not recruiting, University of Southern California | Trial primary completion date: Dec 2025 --> Jun 2026

P=N/A, N=60, Not yet recruiting, IRCCS San Raffaele

The LAC-TME classifier, integrating metabolic and immune data, offers a new tool for ccRCC prognosis and treatment guidance. Further validation is needed to confirm its clinical potential, reflecting the ongoing need for robust medical research.

P=N/A, N=20, Not yet recruiting, The Royal Wolverhampton Hospitals NHS Trust

NNMT is a promising prognostic biomarker and potential therapeutic target in ccRCC, supported by transcriptomic, clinical, and functional validation. While the prognostic relevance of HILPDA remains inconclusive, its metabolic associations suggest potential biological significance. Further studies with larger cohorts and in vivo validation are warranted.

We observed moderate-to-weak evidence supporting causal effects of alcohol consumption on risk of head/neck, oesophageal, and colorectal cancer, inconsistent evidence for liver cancer, and no evidence for breast cancer. Overall, human genetic data do not provide evidence that alcohol consumption is a cause of all cancers and suggest there may even be inverse associations with certain cancer types.

P3, N=904, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting